Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

​Dr. Shah on the Potential of Vaccine-Based Therapy in Multiple Myeloma

September 28th 2021

Nina Shah, MD, discusses the potential of vaccine-based therapies in multiple myeloma.

Dr. Popat on Weighing Belantamab Mafodotin–Related Toxicities in Multiple Myeloma

September 27th 2021

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses the toxicities associated with belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Dr. Cohen on CARTITUDE-2 Data With Cilta-Cel in Multiple Myeloma

September 27th 2021

Adam D. Cohen, MD, discusses outcomes with ciltacabtagene autoleucel, as demonstrated in the phase 2 CARTITUDE-2 study in patients with multiple myeloma.

Dr. Shah on Key Findings From the KarMMa Trial in Multiple Myeloma

September 24th 2021

Nina Shah, MD, discusses key findings from the phase 2 KarMMA trial in relapsed/refractory multiple myeloma.

Rapid Readouts: IKEMA Subgroup Analysis in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics

September 24th 2021

A. Timothy Schmidt, MD, discusses data from the subgroup analysis of the IKEMA study of isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma and high-risk cytogenetics that was presented at the American Society of Clinical (ASCO) 2021 Annual Meeting.

Dr. Sborov on Mitigating Monoclonal Antibody–Associated Toxicities in Multiple Myeloma

September 23rd 2021

Douglas W. Sborov, MD, MS, discusses mitigating toxicities associated with monoclonal antibodies in multiple myeloma.

Dr. Van Rhee on the Clinical Implications of CAR T-Cell Therapy in Relapsed/Refractory Myeloma

September 17th 2021

Frits van Rhee, MD, PhD, discusses the clinical implications of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

Dr. Baljevic on the FDA Approval of the ICARIA-MM Regimen in Relapsed/Refractory Multiple Myeloma

September 16th 2021

Muhamed Baljevic, MD, discusses the FDA approval of isatuximab-irfc in combination with pomalidomide and low-dose dexamethasone in relapsed/refractory multiple myeloma.

Dr. Shah on the Current State of Cellular Therapy in Multiple Myeloma

September 15th 2021

Nina Shah, MD, discusses the current state of cellular therapy in multiple myeloma.

Dr. Sborov on the Toxicities Associated With Novel Therapies in Multiple Myeloma

September 13th 2021

Douglas W. Sborov, MD, MS, discusses the toxicities associated with novel therapies in multiple myeloma.

Dr. Schjesvold on OCEAN Trial Takeaways With Melflufen in Relapsed/Refractory Myeloma

September 12th 2021

Fredrik Schjesvold, MD, PhD, discusses key takeaways from the phase 3 OCEAN trial that was done in patients with relapsed/refractory multiple myeloma.

Melflufen/Dexamethasone Improves PFS in Transplant-Naïve Relapsed/Refractory Multiple Myeloma

September 12th 2021

Melphalan flufenamide (melflufen) plus dexamethasone demonstrated an improvement in progression-free survival vs pomalidomide/dexamethasone in patients with transplant-naïve relapsed/refractory multiple myeloma.

MRD-Based Consolidation Dara-KRd Elicits Rapid Responses in Newly Diagnosed Myeloma

September 11th 2021

Minimal residual disease–based consolidation therapy comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone was found to induce quick responses and unprecedented rates of MRD negativity in patients with newly diagnosed multiple myeloma.

Dr. Anderson on Updated KarMMa Data With Ide-Cel in Multiple Myeloma

September 10th 2021

Larry Anderson, MD, PhD, discusses outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma, as demonstrated in the phase 2 KarMMa trial.

Elranatamab Alone or Plus Lenalidomide Shows Early Efficacy, Safety in Heavily Relapsed Myeloma

September 10th 2021

Elranatamab elicited encouraging responses with a manageable toxicity profile when used alone or in combination with lenalidomide in patients with relapsed/refractory multiple myeloma, with efficacy observed even in those who received prior BCMA-directed therapy or who were triple-class refractory, according to data from the phase 1 MagnetisMM-1 trial.

Cilta-Cel Continues to Yield Deep, Durable Response in Relapsed/Refractory Myeloma

September 10th 2021

A single dose of ciltacabtagene autoleucel continued to elicit early, deep, and durable responses and showcase a manageable safety profile in heavily pretreated patients with multiple myeloma.

Cilta-Cel Emerges as Potential CAR T-Cell Option in Relapsed/Refractory Multiple Myeloma

September 10th 2021

The CAR T-cell therapy ciltacabtagene autoleucel has emerged as a potentially durable treatment strategy for patients with relapsed/refractory multiple myeloma who have progressed on 1 to 3 prior lines of treatment and are refractory to lenalidomide.

Dr. Martin on the Utility of Quadruplet-Based Regimens in Relapsed/Refractory Multiple Myeloma

September 10th 2021

Thomas G. Martin, MD, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma.

Ide-Cel Maintains Clinical Activity With Long-Term Follow-Up in Relapsed/Refractory Multiple Myeloma

September 10th 2021

Idecabtagene vicleucel continued to elicit frequent, deep, and durable responses among patients with heavily pretreated relapsed/refractory multiple myeloma irrespective of whether patients received 3 or at least 4 prior therapies.

Talquetamab Continues to Impress in Relapsed/Refractory Multiple Myeloma

September 10th 2021

Talquetamab, an off-the-shelf T-cell redirecting, GP3C5D-targeting agent, has continued to show promising clinical activity in patients with relapsed/refractory multiple myeloma, especially when given at the recommended phase 2 dose of 405 µg/kg weekly in subcutaneous formulation.

NEXT PAGE
PREVIOUS PAGE